FDA hits leukemia study with partial clinical hold
The FDA has placed a partial clinical hold on Xencor’s Phase I study of XmAb14045 on safety concerns.
Read More
Tag: Xencor
Mixed data for Xencor’s SLE drug
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
Read More
Novartis picks up bispecific antibodies from Xencor
Novartis has signed a collaboration and licensing deal with California biotech Xencor for access to its bispecific antibody technology and rights to develop and commercialise two of the latter’s flagship experimental therapeutics.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
